Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ-1: Durvalumab plus gemcitabine/cisplatin vs placebo plus gemcitabine/cisplatin in first-line advanced biliary tract cancer
2023-507405-34-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer comparing Durvalumab + gemcitabine + cisplatin with Placebo + gemcitabine + cisplatin (2 arms). Primary endpoint: Overall survival. Planned start Jun 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2023-507405-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507405-34-00.